| 3.55 0.67 (23.26%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.42 | 1-year : | 5.31 |
| Resists | First : | 3.78 | Second : | 4.55 |
| Pivot price | 3.05  |
|||
| Supports | First : | 2.55 | Second : | 2.12 |
| MAs | MA(5) : | 3.08 |
MA(20) : | 3.19 |
| MA(100) : | 2.33 |
MA(250) : | 1.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.7 |
D(3) : | 39.7 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 4.55 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QNCX ] has closed below upper band by 6.7%. Bollinger Bands are 35.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.68 | 3.68 - 3.7 |
| Low: | 2.91 - 2.93 | 2.93 - 2.95 |
| Close: | 3.52 - 3.55 | 3.55 - 3.58 |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Thu, 15 Jan 2026
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Mon, 12 Jan 2026
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential - Seeking Alpha
Tue, 06 Jan 2026
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com
Tue, 30 Dec 2025
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Growth in Short Interest - MarketBeat
Mon, 15 Dec 2025
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
Wed, 26 Nov 2025
Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 9.3 (%) |
| Held by Institutions | 24.8 (%) |
| Shares Short | 2,060 (K) |
| Shares Short P.Month | 1,370 (K) |
| EPS | -1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -247.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -2.96 |
| PEG Ratio | 0 |
| Price to Book value | 177.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|